|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS: | |||||||||
| Cash and cash equivalents | |||||||||
| Marketable securities – InterCure Ltd. | |||||||||
| Trade receivable (net of allowance for credit losses of $0 and $36 at December 31, 2025 and 2024, respectively) | |||||||||
| Prepaid expenses and other current assets | |||||||||
| Warrants, net | |||||||||
| Total current assets | |||||||||
| NON-CURRENT ASSETS: | |||||||||
| Fixed assets, net | |||||||||
| Intangible assets, net | |||||||||
| Goodwill | |||||||||
| Long-term bank deposit | |||||||||
| Total Non-current assets | |||||||||
| Total assets | |||||||||
| CURRENT LIABILITIES: | |||||||||
| Loans and credit from banking corporations | |||||||||
| Accounts payable | |||||||||
| Warrants, net | |||||||||
| Convertible loan from shareholder | |||||||||
| Total current liabilities | |||||||||
| NON-CURRENT LIABILITIES: | |||||||||
| Warrants | |||||||||
| Deferred tax liability, net | |||||||||
| Total Non-Current liabilities | |||||||||
| EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY: | |||||||||
| Share capital - ordinary shares of NIS 0.1 par value: Authorized December 31, 2025 and 2024 - 1,450,000,000; Issued and outstanding - 946,243,356 on December 31, 2025 and 881,385,256 on December 31, 2024; | |||||||||
| Additional paid in capital | |||||||||
| Reserve from transactions with non-controlling interests | |||||||||
| Accumulated deficit | |||||||||
| Total equity | |||||||||
| Total liabilities and equity | |||||||||
Loading...